Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers

Area of Science:

• Pharmacogenomics
• Health Services Research
• Genetics and Personalized Medicine

Background:

• Preemptive pharmacogenetic testing offers potential for optimizing medication therapy.
• Payer decisions significantly impact the implementation of pharmacogenetic technologies.
• Understanding payer perspectives is crucial for advancing preemptive pharmacogenetics.

Purpose of the Study:

• To investigate US payers' knowledge, awareness, and perspectives on preemptive pharmacogenetic testing.
• To identify barriers and facilitators to the reimbursement of pharmacogenetics.
• To inform policy development for preemptive pharmacogenetic testing implementation.

Main Methods:

• Qualitative study utilizing semistructured interviews with payer representatives.
• Online survey for participant screening.
• Thematic analysis of interview transcripts using a blended inductive and deductive approach.

Main Results:

• Key findings include payer concerns regarding clinical utility and limited exposure to preemptive germ-line testing.
• Payer preference for randomized controlled trial outcomes and demonstrated impact on clinical decision-making.
• Concerns about downstream costs, benefit predictability, and influence of regulatory bodies (FDA, CMS).

Conclusions:

• Barriers and facilitators exist for developing cohesive pharmacogenetic reimbursement policies.
• The preemptive testing model presents unique implementation challenges.
• Future research should prioritize prospective outcome studies, target population definition, and predictive economic models.